| |
May 1 - 3, 2023 | Jersey City, NJ Don’t miss the opportunity to gain best practices in medical affairs strategy development and ensuring scientific materials are created and shared in a regulatory compliant manner to internal/external stakeholders and thought leaders. Take advantage of the Early Bird Rates, Register Today! .png)
|
|
Today's Big NewsFeb 8, 2023 |
|
Tuesday, February 28, 2023 | 11am ET / 8am PT The heavy lifting for the pharmaceutical industry to comply with the November 2023 DSCSA go-live date is still ongoing. One item now finalized is to ensure that the required data exchange through the supply chain is only done with trusted, authorized, and registered trading partners. Join us for this discussion to stay up-to-date on this important legislation and be prepared for compliance. Register now. 
|
|
| By Angus Liu The calls for a new Bayer CEO have been answered. Bill Anderson, most recently Roche’s pharma chief, will become Bayer’s new group CEO starting in April. |
|
|
|
By Max Bayer With few avenues available to budding biotechs looking for funding, the pressure to ink licensing agreements was palpable at the Biotechnology Innovation Organization's CEO and Investor Conference in New York. |
By Andrea Park As Surmodics is forced to delay the launch of its SurVeil drug-coated balloon by several months at least, erasing some expected earnings from its 2023 forecasts, the company is looking to cut costs in other areas. |
By Angus Liu As Vertex Therapeutics nears completion of a historic FDA submission, the rare disease specialist has depicted a rosy launch picture for what could become the first CRISPR-based gene editing therapy. |
|
Evidation and Fierce Biotech conducted a survey of industry professionals to gather insights on the role integrated evidence strategies play in their businesses, as well as the impact of these strategies in helping to deliver better health outcomes. Access the findings from this important survey now. 
|
|
By Gabrielle Masson While COVID-19 may have briefly held down the average cost of developing a drug while inflating the potential returns, the party is well and truly over. At least that's what a report from Deloitte indicates, with Big Pharma back on the pre-pandemic path of spending ever more to make a medicine with shrinking rewards to show for it. |
By Conor Hale The artificial intelligence program is designed to provide real-time feedback to clinicians conducting cardiac ultrasound exams. |
By Ben Adams You may have been enthralled by the Adele/Harry Styles drama, but Big Pharma also had a big night at the 65th Annual Grammy Awards this week. |
By Fraiser Kansteiner Almost a year to the day after Pfizer launched its suit against Regor and two former employees at the head of the biotech—Min Zhong and Xiayang Qiu—U.S. Magistrate Judge Thomas Farrish has ordered the Big Pharma to fork over 35 emails and text messages with the FBI related to the defendants. |
By Zoey Becker Teva's new CEO Richard Francis has his work cut out for him. After a year of declining sales for most products in 2022, the company plans to lean on growth drivers Austudo and Ajovy in 2023 as it looks forward to a Humira biosimilar launch. |
By Andrea Park The exact financial terms of the acquisition weren’t disclosed, but Lantheus said that the stock-based deal would comprise not just an upfront payment, but also additional milestone and royalty payouts. |
Fierce podcasts Don't miss an episode |
| In this week's episode of "Podnosis," we discuss how providers can and should recognize and respond to the culturally diverse needs of the Latino community. We also talk about what private healthcare plans can do given the explosion of enrollment in ACA exchanges. |
|
|---|
|
|
|
The global demand for biologics is projected to increase considerably by 2030, but the challenges, risks, and costs are also growing. For pharma companies looking to bring a new biologic to market, meeting clinical trial milestones can be difficult. To access important insights, download this executive summary now. .png)
|
|
Whitepaper Discover the Power of Small with NanoplasmidTM – the next-generation plasmid for manufacturing today’s cell and gene therapies. Sponsored by: Aldevron |
Whitepaper This paper explores the cost drivers behind gene therapies and how they are likely to evolve in the coming years. Sponsored by: Blue Matter |
Whitepaper Exploring the biology of G Protein-Coupled Receptors (GPCRs) and outlining a novel approach for developing therapeutics against previously undruggable GPCRs Sponsored by: Orion Biotechnology |
Whitepaper Learn more about critical success factors for your next launch based on the experience of 100+ pharma product launches. Sponsored by: Herspiegel Consulting |
Whitepaper RCTs with digital twins require fewer control patients and shorten trial timelines for Alzheimer's disease. Sponsored by: Unlearn AI |
Whitepaper What makes nucleotides suitable for current good manufacturing practices? Sponsored by: Thermo Fisher Scientific |
On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| May 1-3, 2023 | Jersey City, NJ |
|
|
| |
|
